Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767948 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01767948 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 30 participants.
The verdict
NCT01767948, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of PCI 32765 in participants with mild, moderate, or severe hepatic impairment.
Interventions
- DRUG PCI-32765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767948
The ClinicalTrials.gov registry entry for NCT01767948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCI-32765 is the first listed.
NCT01767948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01767948 about?
NCT01767948 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment". The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of PCI 32765 in participants with mild, moderate, or severe hepatic impairment.
What is the current status of trial NCT01767948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01767948?
The interventions under investigation include: PCI-32765 (DRUG).
Who is sponsoring clinical trial NCT01767948?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.